Cepheid Unveils Prelim 4Q Results - Analyst Blog
January 10 2013 - 9:40AM
Zacks
Recently, Cepheid
(CPHD) reported selected results for fourth quarter of 2012 based
on preliminary analysis. The molecular diagnostic company also
provided updates on the ongoing manufacturing issues and Xpert test
availability.
Elementary Results for the Fourth Quarter
Cepheid currently expects revenues of about $92 million in the
fourth quarter, up approximately 12.5% year over year. Growth was
led by higher-than-expected revenues from commercial clinical
reagents. However, it trails the company’s guidance as well as the
current Zacks Consensus Estimate of $94 million.
Cepheid envisages commercial clinical revenues to be around $72
million, higher than the prior outlook of approximately $69
million. Commercial clinical revenues were primarily driven by
higher sales of Xpert Flu, Xpert MRSA and Xpert C.difficile as
these offerings accounted for 30% normalized growth on a
year-over-year basis. Moreover, placements of 59 GeneXpert systems
in North America (accounting for lion’s share of Cepheid’s
revenues) are expected in the quarter under review.
Clinical revenues from High Burden Developing Country (HBDC)
program is expected to be in the neighborhood of $10 million, lower
than the company’s forecast of $16 million. Cepheid failed to meet
its own expectations due to choppy system placements in target
countries and supply lag in the overseas operations. However,
management expects to turn the tables in the first quarter of
2013.
As announced earlier, Cepheid expected adjusted commercial gross
margin to be marginally above 60% and after considering HBDC
business, the company targeted adjusted gross margin in the 51−52%
range. Given the fact that Cepheid’s commercial clinical business
is a high gross margin division relative to HBDC revenues, we
expect Cepheid to achieve the target for gross margin for the
fourth quarter.
Earlier, the company envisaged loss per share in the band of 1 cent
and 3 cents on a GAAP basis and adjusted earnings in the band of 10
cents and 12 cents for the fourth quarter. Based on the preliminary
analysis, Cepheid expects to surpass the high end of its earlier
guidance for earnings. The current Zacks Consensus Estimate for the
fourth quarter is loss of 2 cents.
Other Updates
As Cepheid faces a higher-than-expected demand for its Xpert tests
for the fourth quarter, the company’s constant efforts to address
manufacturing concerns is likely to pay off. The company disclosed
that it is closer to returning to normal manufacturing operations
after addressing the underlying issues, which negatively affected
the financial results in the second half of 2012.
Cepheid expanded its capacity by setting up another Reagent on
Board Automation Line (ROBAL) in Sunnyvale. The company is also set
to round off its second ROBAL line at its manufacturing facility in
Sweden and initiate related functions in the second half of
2013.
These initiatives are expected to yield positive results for
Cepheid as the demand for Xpert offerings, mainly Xpert MRSA and
Xpert Flu, continue to surge. While we believe that the disruption
in the company’s manufacturing operations was temporary and waning,
Cepheid’s efforts and management commentary encourage our
confidence.
With a lukewarm end to 2012 for Cepheid, we look forward to 2013
with full optimism as the current headwinds take a backseat. The
company has several catalysts to support long-term growth. We
currently have a long-term Neutral recommendation on Cepheid. The
stock carries a Zacks Rank #2 (Buy). Other medical sector stocks
carrying a Zacks Rank #2 are Cyberonics Inc.
(CYBX) and MAKO Surgical Corp. (MAKO).
CEPHEID INC (CPHD): Free Stock Analysis Report
CYBERONICS INC (CYBX): Free Stock Analysis Report
MAKO SURGICAL (MAKO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Mako Surgical Corp. (MM) (NASDAQ:MAKO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mako Surgical Corp. (MM) (NASDAQ:MAKO)
Historical Stock Chart
From Jul 2023 to Jul 2024